Bio-Rad Laboratories Class ABIO
Market Cap: $9.19B
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 8,030
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
6.69% more ownership
Funds ownership: 77.83% [Q1] → 84.53% (+6.69%) [Q2]
5% less funds holding
Funds holding: 455 [Q1] → 430 (-25) [Q2]
14% less capital invested
Capital invested by funds: $6.3B [Q1] → $5.41B (-$894M) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 176
30% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 83
38% less call options, than puts
Call options by funds: $6.34M | Put options by funds: $10.2M
45% less funds holding in top 10
Funds holding in top 10: 11 [Q1] → 6 (-5) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wells Fargo Brandon Couillard 36% 1-year accuracy 4 / 11 met price target | 3%upside $340 | Equal-Weight Initiated | 27 Aug 2024 |
RBC Capital Conor McNamara 39% 1-year accuracy 15 / 38 met price target | 22%upside $401 | Outperform Reiterated | 16 Aug 2024 |
RBC Capital Conor McNamara 39% 1-year accuracy 15 / 38 met price target | 22%upside $401 | Outperform Maintained | 2 Aug 2024 |
Citigroup Patrick Donnelly 72% 1-year accuracy 23 / 32 met price target | 6%upside $350 | Neutral Maintained | 2 Aug 2024 |
Financial journalist opinion
Based on 5 articles about BIO published over the past 30 days